SALT POINT STRATEGIES ON BEHALF OF THE RITEDOSE CORPORATION

Lobbying client · District of Columbia · filed 2026 to 2026

Strategic consulting. / Pharmaceutical CDMO and Preparedness Manufacturer.

$60,000 Reported spend

3 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 3 filings. Everything on this page is grouped by the client's LDA id (71682), not by name.

Firms hired 1

ALB SOLUTIONS $60,000 3 filings

Reported by year 1 year

2026 $60,000 3 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

Food & Drug Administration (FDA) 2
Health & Human Services, Dept of (HHS) 2
HOUSE OF REPRESENTATIVES 2
SENATE 2

Recent filings 3 total

Q2

ALB SOLUTIONS

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $30,000 income · posted Jul 16, 2026

View → Q1

ALB SOLUTIONS

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $30,000 income · posted Apr 15, 2026

View → RR

ALB SOLUTIONS

1st Quarter (Jan 1 - Mar 31) 2026 · posted Mar 10, 2026

View →

Affiliated organisations 1

THE RITEDOSE CORPORATION United States of America named on 1 filing

Section 6 of the LD-2: organisations that contribute to or take part in this client's lobbying.

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.